Multiple Primary Malignancies Epidemiology and Management

Multiple primary malignancies refer to the occurrence of two or more distinct cancers in a single individual, either synchronously or metachronously. With rising cancer survival rates and advances in diagnostic imaging and molecular profiling, the identification of additional primary tumours has become more frequent. Epidemiological studies demonstrate that survivors of common cancers—such as breast, lung and colorectal—face elevated risks of subsequent malignancies. Risk factors include age at first diagnosis, genetic predisposition, lifestyle exposures (notably tobacco and alcohol), and the long-term effects of treatment modalities such as radiotherapy and cytotoxic chemotherapy. The latency between first and subsequent primaries often shortens with each new tumour, underscoring the importance of tailored surveillance protocols. Management strategies now integrate precision medicine approaches, incorporating histology-specific risk models, tumour mutational burden profiling, and patient-derived organoid platforms to guide personalised treatment. Multidisciplinary coordination among oncologists, surgeons and genetic counsellors is essential to optimise outcomes, mitigate overlapping toxicities and maintain quality of life over extended survivorship.

Research from Nature Portfolio

A recent pan-cancer analysis of over 11,000 patients revealed that the incidence of multiple primary cancers has increased to 8.5–13.1 per cent since 2000. Older age, male sex, early stage at first diagnosis and certain ethnic backgrounds were independent risk factors. Patients with multiple primaries exhibited shorter overall and disease-free survival compared with those with a single tumour, with the greatest divergence driven by age and initial tumour stage. Notably, skin cutaneous melanoma cases in the multiple-primary cohort showed a significantly higher tumour mutational burden, which correlated with improved survival and suggests a potential biomarker for immunotherapy selection in this context.

Multiple Primary Malignancies Epidemiology and Management publication trend

The graph below shows the total number of articles in multiple primary malignancies epidemiology and management across all publications each year (not limited to Nature Index journals).

Technical terms

Multiple primary malignancies (MPM): The occurrence of two or more primary tumours in one individual, excluding metastases or recurrences.

Synchronous tumours: Primary malignancies diagnosed within six months of each other.

Metachronous tumours: Primary malignancies diagnosed more than six months apart.

Standardised incidence ratio (SIR): The ratio of observed to expected cancer cases in a study population, adjusted for age, sex and other demographics.

Tumour mutational burden (TMB): The number of somatic mutations per megabase of tumour DNA, used to predict response to immunotherapy.

Overall survival (OS): The duration from diagnosis or treatment initiation to death from any cause.

Disease-free survival (DFS): The interval after primary treatment during which no signs of cancer are detected.

References

1. Histology-specific standardized incidence ratio improves the estimation of second primary lung cancer risk. BMC Medicine (2024).
2. Emerging trends in the coexistence of primary lung Cancer and hematologic malignancy: a comprehensive analysis of clinicopathological features and genetic abnormalities. Cancer Cell International (2024).
3. Incidence and Characteristics of Multiple Primary Cancers: A 20-Year Retrospective Study of a Single Cancer Center in Korea. Cancers (2024).
4. A pancancer analysis of the clinical and genomic characteristics of multiple primary cancers. Scientific Reports (2024).
5. Precision Treatment of Metachronous Multiple Primary Malignancies Based on Constructing Patient Tumor-Derived Organoids. Biomedicines (2024).